John Rundback, Medical Director of the Interventional Institute at Holy Name Medical Center in Teaneck, New Jersey enrolled the first patient. The trial will recruit additional patients at
ProForm Select aligns our solid-state, process chemistry and formulation development centers of excellence in Weert, The Netherlands, Germantown, Wisconsin and Wilmington, North Carolina. These groups are focused on
Freund Pharmatec, a wholly-owned Irish subsidiary of Freund Corporation, is a specialist drug delivery technology company focused on proprietary mini-encapsulation and layering technologies. Through this acquisition, Sigmoid will
The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer antibody-drug conjugate (ADC) platform and grants Mersana an option
Eisai and Esteve will launch the new indication for the adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (=12 years) with idiopathic generalised epilepsy
The EMA is currently reviewing the completeness of the application before initiating the official review process. It is expected that the Committee for Orphan Medicinal Products (COMP) will
Osimertinib is indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment with an EGFR tyrosine kinase inhibitor (TKI). Eligibility for treatment with osimertinib will be dependent
The agreement provides ViaCyte with an exclusive license to all BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to
In this letter, the FDA communicated that an additional Phase 3 clinical trial for MCNA would be necessary to adequately establish MCNA’s efficacy and safety. The FDA also
In addition, the company announced that it is on track to start Phase II clinical testing in the first half of this year, and that the results of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.